



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 15th June 2022

PRESENT:

| | |
|------------------------|---|
| Dr S Ramtoola (SR) | Consultant Physician, ELHT (Chairperson) |
| Dr L Rogan (LR) | Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG |
| Mr V Goodey (VG) | Assistant Director of Pharmacy, Clin Service ELHT |
| Mr J Vaughan (JV) | Senior Medicines Commissioning Pharmacist NHS EL/BwD |
| Ms Ana Batista (AB) | Medicines Information Pharmacist ELHT |
| Mr U Akram (UA) | Deputy Lead Pharmacist, LS CFT |
| Ms F Iqbal (FI) | Senior Pharmacist NHS BwD CCG |
| Mr C Woods (CW) | Head of Contracting and Costing, Finance |
| Mrs H. Robinson (HR) | Divisional Lead Pharmacist – MEC |
| Dr F Shah (FS) | GP/Consultant MFOP & Diabetes |
| Mr Neil Fletcher (NF) | Director of Pharmacy ELHT |
| Dr S Bhattacharya (SB) | ED Consultant |

IN ATTENDANCE:

| | |
|---------------------|-----------------------------------|
| Dr A Hafejee (AH) | Dermatology Consultant |
| Mr W Price (WP) | Dermatology Specialist Pharmacist |
| Mr K M-Pillai (KMP) | Urology Consultant |
| Dr I Gkikas (IG) | Gastroenterology Consultant |
| Mr K Patel (KP) | Gastroenterology Pharmacist |
| Mr A Ahmed (AA) | Paediatrics Specialist Pharmacist |

2022/095: APOLOGIES:

| | |
|-------------------|---|
| Ms L Prince (LP) | Medicines Management Technician, EL CCG |
| Dr S Jackson (SJ) | Clinical Commissioning Group MM Lead, GP EL |
| Dr J Shihab (JS) | Consultant Neonatologist |

2022/096: DECLARATION OF INTEREST

None



2022/097: MINUTES OF MAY TEAMS MEETING:

Amendment to page 2: item **2022/080 – Efmody®**

Changed to “*requested for use in adolescent patients aged 12 years and over and adults with congenital adrenal hyperplasia (CAH) who have sub optimal control on conventional treatment.*”

Resolved: item closed once correction made

2022/098: MATTERS ARISING:

2022/068: Differences in RAG:

Feedback submitted to LSCMMG

Resolved: item closed

2022/080: NPR Efmody®:

Submitted to LSCMMG for review, awaiting their decision.

Resolved: item closed

2022/081e: Saxenda® 6mg/mL:

Awaiting update from Adam Grainger at LSCMMG but currently red in the formulary.

Resolved: item closed

2022/089: Current and proposed RAG status for liothyronine

ELMMB comments fed back to LSCMMG however the final decision (amber) differs from ELMMB position (black). Concerns discussed regarding adopting the amber position.

Action: Dr SR will discuss with endocrinology colleagues to decide if locally we adopt the suggested amber or add it as red.

2022/063 (a,b): Tralokinumab FOC application and Upadacitinib FOC application

Requested to rediscuss. WP has got in touch with David Prayle at LSCMMG who is still reviewing their position on Free of Charge Schemes (FOC) and has forward him the FOC framework that was discussed and approved at ELMMB in October 2021 for local use. Only patients who have exhausted all other options will be put on these medicines. If NICE doesn't approve these drugs, the patients will still be able to continue treatment at a reduced price, almost free (£1), until clinician decides that the treatment is not appropriate. Expected less than 10 patients a year. NICE TA expected in October 2022. FOC for both drugs accepted.

Resolved: item closed

2022/099 Unlicensed Medicine Request:

- a. **Boric acid 600mg vaginal capsule** requested by Dr C Owen (Dermatology Consultant) for Recurrent Vulvovaginal Candidiasis with non-albicans Candida species and azole resistance as per national guideline. There is no licensed product on the market in the UK. WP stated it will be used in a very small number of patients and only when other options, such as nystatin have failed. Initially requested as amber but concerns raised by Dr SJ as the product is a special and it wouldn't be appropriate. Nystatin pessaries, which were approved previously as amber, are also an unlicensed medicine in the UK but we are using a foreign licensed preparation and for that reason it was requested to stay amber.



Resolved: Boric acid vaginal pessaries to be added to formulary as RED, nystatin pessaries to continue AMBER

2022/100: New Product Request

- a. **Decapeptyl SR 22.5 mg powder for suspension for injection** requested by Mr Mohan-Pillai (Consultant Urologist) as preferential hormone treatment of high-risk localised or locally advanced prostate cancer, as an adjuvant to radical treatments for localised or locally advanced prostate cancer, and for metastatic prostate cancer. This will be given every 6 months, replacing the current hormonal treatment which is given every 3 months. This is already common practice on other hospitals.

Resolved: Approved for use

Traffic Light: AMBER

- b. **Vitamin A Palmitate 100000 units per 2 mL injections** requested by Dr Gkikas (Consultant Gastroenterologist) for Vitamin A replacement in chronic liver disease patients as per circulated Leeds Guidance, the tertiary centre. Treatment will be initiated and dispensed by hospital; a medication authorization form will be given to the patient to take to their local treatment room for administration of the injections. Twenty-five patients expected to be treated per year.

Action: Unlicensed medicine form to be completed and submitted to ELMMB for acknowledgment only in July's meeting by KP.

Approved for use

Traffic Light: RED

2022/101 Formulary Updates

- a. **Alimemazine 7.5mg/5mL** - approved for as second line after promethazine/continuation when initiated by tertiary centres for multiple indications e.g., insomnia/sedation. Use restricted to paediatrics only.

Traffic Light: AMBER

- b. **Dicycloverine 10mg/5mL** - approved for GI disorders, for continuation when initiated by tertiary centres. Use restricted to paediatrics only.

Traffic Light: AMBER

- c. **Xenidate XL** - branded generic to be add to formulary as an alternative to deal with shortages of preferred formulary products.

**Traffic Light: AMBER
Shared Care**

- d. **Trimbow MDI** – for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2-agonist. As per SCC decision

Traffic Light: GREEN

2022/102 LSCMMG Consultations - June 2022

- a. **Sodium zirconium cyclosilicate RAG consultation (currently RED, proposed AMBER 0)** - Agreed



b. Amiodarone SCG addition of indication: postoperative atrial fibrillation (post-CABG) - Yes for indication, Maybe for supply: members agreed that the provider should supply the initial course of amiodarone however there were concerns regarding what happens if patients are not seen within the 6 weeks which may leave the patient without medication until the follow up appointment.

c. Paliperidone 6 monthly injection – Agreed.

Resolved: AB to feedback to LSCMMG.

2022/103 LSCMMG Recommendations – May 2022

- a. Axial spondylarthritis pathway – Updated
- b. Heart Failure - Primary Care Guideline for the Use of SGLT-2 Inhibitors in Reduced Ejection Fraction Heart Failure – Added

Resolved: Acknowledged by ELMMB

2022/104 Strategic Commissioning Committee (SCC) Decisions – May 2022

- a. Trimbaw MDI for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2-agonist

Resolved: Acknowledged by ELMMB and added to formulary as per formulary section above

2022/105 NICE Guidance - May 2022

None of interest

2022/106 NICE Recommendations – May 2022

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy is recommended as an option by NICE. Approved in line with NICE TA788

NHS England Commissioned

Traffic Light: RED

Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations is recommended as an option by NICE. Approved in line with NICE TA789

NHS England Commissioned

Traffic Light: RED

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) is not recommended as an option as per NICE TA790.

Traffic Light: BLACK

Resolved: Items acknowledged by ELMMB



Romosozumab for treating severe osteoporosis is recommended as an option by NICE.
Approved in line with NICE TA791
ICS/CCG Commissioned **Traffic Light: TBC**

Discussion regarding traffic light; proposed either amber or red by LSCMMG. They have requested feedback from each organisation.

ELMMB members thought that it should probably be RED and managed via homecare. Otherwise, if classed as AMBER, then a shared care guideline should be developed.

Action: AB to feedback to Adam Grainger at LSCMMG.

2022/107 NICE Highly Specialised Technologies – May 2022

Selumetinib recommended for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

Resolved: item acknowledged by ELMMB

2022/108 EAMS (Early access to medicines scheme) – May 2022

Efgartigimod alfa in the treatment of myasthenia gravis (gMG)

Resolved: Item acknowledged by ELMMB

Standing Items:

2022/109 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)

DRAFT LSCMMG minutes 14.05.2022

Resolved: Minutes acknowledged.

2022/110 For Action/Information: Lancashire & South Cumbria FT Drugs and Therapeutics Committee

Drugs and Therapeutics Committee Meeting Minutes and Action Tracker from the 26th May 2022

Resolved: acknowledged by ELMMB.

2022/111 For Action/Information: Antimicrobial Stewardship Committee (ASC)

ASC minutes for 8th March 2022 meeting (April's meeting cancelled)

Resolved: acknowledged by ELMMB.



DATE OF NEXT MEETING – Wednesday 20th July 2022 12.30pm via ‘Microsoft Teams’

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 15th June 2022

| MINUTE NUMBER | DESCRIPTION | ACTION | DATE |
|----------------------|---|---------------|-------------|
| 2021/101b | ELMMB Membership A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will required review as a result of that | LR/VG | Sep 22 |
| 2022/089 | Current and proposed RAG status for liothyronine Dr SR to gather endocrinology team opinion whether we add it to our local formulary as Amber (as per recommendations) or Red. | SR | July 22 |
| 2022/100b | Vitamin A Palmitate 100000 units per 2 mL injections Unlicensed medicine form to be completed and submitted to ELMMB for acknowledgment only in July's meeting by KP | KP/AB | July 22 |
| 2022/106 | NICE Recommendations – May 2022 – TA791 (Romosozumab for treating severe osteoporosis) AB to feedback to Adam Grainger at LSCMMG the ELMMB traffic light opinion. | AB | July 22 |